Toleranzia AB (publ) ("Toleranzia" or the "Company") has today, in connection with the upcoming merger between Toleranzia and Flerie (the "Merger"), which was announced through a press release on 25 March 2025, submitted an application for delisting of the Company's shares from Nasdaq First North Growth Market. The delisting is conditional upon the completion of the Merger.
The Merger is expected to be registered with the Swedish Companies Registration Office (Bolagsverket) on 19 August 2025, and the last day of trading in Toleranzia's shares is therefore expected to be 18 August 2025. Upon registration of the Merger with the Swedish Companies Registration Office, Toleranzia will be dissolved and its assets and liabilities transferred to Flerie, thereby completing the Merger.
Further information regarding the detailed timeline for delivery of shares in Flerie as merger consideration to the shareholders of Toleranzia will be communicated by Flerie and Toleranzia in due course.
For further information, please contact:
Charlotte Fribert - CEO, Toleranzia
Tel: +46 763 19 98 98
Email: charlotte.fribert@toleranzia.com
About Toleranzia AB (publ)
Toleranzia AB (publ) develops medicines that harness the power of the immune system to treat rare autoimmune diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, just reduce symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on Nasdaq First North Growth Market and Svensk Kapitalmarknadsgranskning AB, +46 (0)8 913 008, ca@skmg.se, is the company's Certified Adviser.
